San Francisco, CA
Dr. Chalberg is a co-founder and CEO of Avalanche, a clinical-stage ophthalmology company focused on the discovery and development of biologics for retinal diseases. Prior to joining Avalanche, Dr. Chalberg worked on the ophthalmology team at Genentech, helping to launch Lucentis, a novel therapeutic for age-related macular degeneration. As a Howard Hughes Medical Institute Fellow at Stanford, his research focused on retinal diseases and technologies for gene therapy. Dr. Chalberg holds an A.B. from Harvard University, where he graduated magna cum laude and Phi Beta Kappa. He earned a PhD in Genetics from the Stanford University School of Medicine and an MBA from the UC Berkeley Haas School of Business.